Core Insights - The US Department of Commerce has initiated an investigation into the national security implications of importing medical devices and healthcare equipment, leading to a decline in medtech stock prices on September 25 [1][3] - The investigation is part of a broader review under Trump's Section 232, which has previously resulted in tariffs on various goods [1][2] Industry Impact - Stock prices for major companies such as GE HealthCare and Becton Dickinson fell by over 4% on September 25, closing at $71.50 and $180.59 respectively, with other companies like Intuitive Surgical and Insulet also experiencing declines [3] - The Department of Commerce is seeking feedback within a 21-day window regarding the national security effects of importing medical devices, consumables, and personal protective equipment [3][4] Areas of Interest - The DOC is particularly focused on potential export restrictions by foreign nations, the feasibility of reducing import reliance, and the impact of foreign government subsidies and predatory trade practices on competitiveness [5] - The Advanced Medical Technology Association (AdvaMed) expressed a cautiously optimistic view regarding the investigation, emphasizing the strength of US medtech manufacturing and the potential benefits of lower tariffs [5][6]

MESA, ARIZONA / ACCESS Newswire / September 26, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) unveiled its AI Facial Health Risk Estimator for early detection of diabetic retinopathy, a leading cause of preventable blindness worldwide. The system analyzes subtle retinal cues captured from standard facial imaging, identifying microaneurysms, hemorrhages, and vascular leakage, allowing for non-invasive, accessible early screening. ...

Core Insights - The 13th China (Mianyang) Science and Technology City International High-tech Expo opened on September 26, 2025, showcasing cutting-edge technologies like artificial intelligence and the low-altitude economy, along with a new exhibition zone for specialized industrial products [1][2] Group 1: Expo Development and Impact - The Expo has evolved into a significant platform for scientific and technological exchange in western China, facilitating over 2,000 technological achievements and attracting more than 5,000 exhibiting enterprises, generating a total transaction value exceeding 100 billion yuan [2] - Mianyang's continuous expansion in the field of scientific and technological innovation reflects its growing vitality as a host city for the Expo [2] Group 2: Mianyang's Innovation Infrastructure - Mianyang, as China's designated Science and Technology City, has established a robust foundation for innovation, including the first large-scale scientific instrument sharing platform and housing 7 national key laboratories and 4 national engineering technology research centers [3] - The city has over 260 national and provincial-level innovation platforms, supporting advancements across various sectors [3] Group 3: Landmark Achievements - Mianyang has achieved significant milestones in medical technology, including the development of a medical cyclotron for domestic production of medical isotopes, addressing a critical material bottleneck for precision cancer diagnosis and treatment [4] - In advanced materials, Mianyang enterprises have achieved large-scale production of flexible display materials, with core technologies ranking among the most advanced globally [4] Group 4: Mechanisms for Technology Transfer - Mianyang has developed effective mechanisms for transforming scientific achievements into practical applications, including university-enterprise matchmaking events and a bundled transformation model, leading to a technology contract transaction value of 20 billion yuan in 2024 [5] Group 5: Local Success Stories - Mianyang GiaStar Magnetic Material Co., Ltd. has created a neodymium iron boron material that reduces production costs by 15-20% while maintaining performance [6] - A collaboration between the China Academy of Engineering Physics and Changhong Group has resulted in the e-Flash radiotherapy device, achieving millisecond-level precision treatment [6] - The local robot industry, exemplified by Sichuan Tianlian Company, is projected to exceed an output value of 3 billion yuan by 2025 [6] Group 6: International Collaboration - Mianyang has established international relationships with 36 cities in 24 countries and collaborates with enterprises from Germany and Japan in various frontier fields, enhancing its role in the global innovation network [7]

Core Insights - Perimeter Medical Imaging AI, Inc. is participating in the "Take the Lead in Breast Cancer Care" summit, which gathers leading breast cancer physicians to discuss advancements in patient care [1][3] - The company's S-Series OCT technology, which received FDA clearance in 2021, allows surgeons to visualize margins during surgery, and an AI-assisted version is currently under FDA evaluation [2][4] Company Overview - Perimeter Medical Imaging AI is based in Toronto and Dallas, focusing on transforming cancer surgery with advanced imaging tools that provide real-time, ultra-high-resolution visualization of excised tissues at the cellular level [4] - The Perimeter S-Series OCT system is FDA-cleared and available across the U.S., while the investigational Perimeter B-Series OCT with ImgAssist AI is undergoing a pivotal clinical trial supported by a grant of up to US$7.4 million from the Cancer Prevention and Research Institute of Texas [4][5] Industry Context - The summit features multi-disciplinary discussions among surgeons, oncologists, pathologists, and genetic specialists, aimed at exploring innovative diagnostics and therapeutic discoveries to improve patient outcomes [3]

Core Viewpoint - CapsoVision, Inc. is actively participating in the 4th Annual ROTH Healthcare Opportunities Conference, highlighting its focus on advanced imaging and AI-enabled capsule endoscopy solutions [1] Company Overview - CapsoVision is a commercial-stage medical technology company dedicated to transforming the detection and diagnosis of gastrointestinal diseases through advanced imaging and AI solutions [3] - The flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that provides high-resolution visualization of the small bowel and supports cloud-based or direct video retrieval [3] - The upcoming product, CapsoCam Colon, features enhanced AI capabilities aimed at non-invasive colon imaging and polyp detection [3] - The company is developing a proprietary platform intended to expand across various gastrointestinal indications, including esophageal and pancreatic disorders [3]

Overview - The company is pleased with its performance in fiscal Q3, highlighting successful product launches and overall execution by the team [1] Group 1: Product Performance - Key product launches, including the Pro iQ single-quad and the 8850, have resonated well in the market [1] - The Infinity III replacement cycle has also contributed positively to the company's performance [1] Group 2: Services Business - The services business is critical for the company, enhancing customer satisfaction and underpinning overall performance [2]

Core Insights - Masimo Corporation has completed the divestiture of its Sound United consumer audio business to HARMAN International, a subsidiary of Samsung Electronics, marking a strategic shift to focus on core healthcare operations [1][7] - The CEO emphasized that this sale is a significant milestone in Masimo's transformation, allowing the company to concentrate on enhancing patient impact, accelerating innovation, and improving margins [2] Financial Implications - The proceeds from the divestiture will primarily be used for share repurchases, indicating confidence in the stock's intrinsic value and a commitment to enhancing shareholder returns [2][9] - Masimo's shares have experienced a 15% decline year-to-date, compared to an 11.6% decline in the industry and a 14.2% gain in the S&P 500 [3] Strategic Rationale - The exit from consumer audio resolves an overhang that had affected investor perception since the acquisition of Sound United in 2022, aligning Masimo's portfolio with long-term healthcare priorities [5][11] - The timing of the sale coincides with improved operational performance in the healthcare segment, which reported double-digit constant-currency growth and over 50% EPS growth in the first half of 2025 [8] Future Growth Initiatives - Following the divestiture, Masimo plans to focus on three growth "waves": enhancing commercial excellence, accelerating intelligent monitoring adoption, and expanding into wearable patient monitoring technologies [8] - The anticipated buyback program is expected to serve as a near-term financial catalyst, with management indicating that repurchases are the most accretive use of proceeds in the current environment [9][10] Market Positioning - The divestiture positions Masimo to evolve into a pure-play medtech leader, better positioned to capture opportunities in large adjacent markets such as capnography, hemodynamics, and brain monitoring, which represent multi-billion-dollar opportunities [11]

MESA, ARIZONA / ACCESS Newswire / September 25, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) announced that its AI Facial Health Risk Estimator now includes early detection and monitoring of glaucoma and cataracts, two leading causes of vision loss globally. Using high-resolution facial and ocular image analysis, the platform detects: Corneal opacity and lens clouding for cataracts Early optic nerve changes and other glaucoma biomarkers This integration allows patients and clinicians to monitor eye ...

About this content About Jamie Ashcroft Jamie Ashcroft, the News Editor for Proactive UK, has developed an impressive career in financial journalism, focusing on the small-cap sector for over fourteen years. Before joining the Proactive team, he was a stockbroker during the global financial crisis, a role that complemented his educational background - a first-class degree in Business and Economics and qualifications in software design and development. As one of the early external hires at Proactive in 20 ...

Core Insights - Algernon Pharmaceuticals has signed a definitive equipment order and financing agreement with Catalyst MedTech for four FDA-cleared Oncovision CareMiBrain™ PET scanner systems, valued at over CAD $4 million, to be used in planned neuroimaging clinics [1][2] - The PET scanners will primarily focus on early-stage detection of Alzheimer's Disease and other neurological conditions, addressing a significant market need [3][4] Financial Terms - The financing agreement includes a 20% deposit, monthly payments at an average annual interest rate of 7%, and a balloon payment after two years [2] - The PET scanner costs represent approximately 80% of the capital required to open a neuroimaging clinic, making this transaction crucial for the company's initiative [2] Market Opportunity - The global economic burden of Alzheimer's was estimated at US$1 trillion in 2019, projected to rise to US$10 trillion by 2050, indicating a substantial market opportunity for Alzheimer's diagnostics and treatment [4] - The recent FDA approval of new Alzheimer's therapies requiring brain-specific PET scans has created a billion-dollar market opportunity in this sector [4] Clinic Operations - The new clinics will be the first dedicated brain-specific PET neuroimaging facilities in the U.S., focusing on early detection of Alzheimer's and other neurological disorders [3] - Each Alzheimer's PET brain scan will cost approximately US$5,000, covered by private insurance, Medicare, and Medicaid [6] Strategic Partnerships - Catalyst MedTech is a leading provider of molecular imaging technology and has secured exclusive distribution rights for the CareMiBrain™ system in the U.S. [7][16] - The partnership will enhance patient access and experience while reducing radiation exposure by up to 25% compared to traditional PET/CT units [8][11] Future Plans - Algernon plans to expand its network of neuroimaging clinics across North America and will soon announce the location of its first U.S. flagship clinic [13] - The company is also changing its name to Algernon Health Inc. to better reflect its focus on Alzheimer's diagnostics [13]